Summerway Capital

Summerway Capital Plc acquired Celadon Medicines via a reverse takeover in 2023, taking the operating company's name and business. The combined entity trades as Celadon Pharmaceuticals on AIM. Summerway no longer functions as a standalone investment company — it is the listed parent of a single operating business focused on pharmaceutical-grade cannabis cultivation and manufacture.

Celadon holds a Home Office license to cultivate high-THC cannabis for medicinal purposes, one of a very limited number issued in the UK. The license imposes strict security, quality, and compliance requirements, creating a barrier to entry that new entrants cannot easily clear. Additionally, the company's manufacturing facility operates to Good Manufacturing Practice standards required for pharmaceutical production.

Revenue comes from two channels. The primary domestic channel is the supply of unlicensed cannabis-based medicinal products to UK patients via private prescriptions written by specialist doctors. The secondary channel, activated in early 2024 following a commercial export announcement, involves wholesale supply of pharmaceutical-grade cannabis flower to distributors in continental Europe. Revenue remains early-stage; the company reported approximately £200,000 for 2023.

According to its original AIM admission documents, Summerway was formed as a special-purpose acquisition company targeting controlling stakes in European small-cap companies, with a generalist buyout mandate. Prior to the Celadon reverse takeover, no completed platform acquisitions were publicly disclosed. The vehicle's pre-Celadon deployment record is effectively nil.

Operational and strategic decisions now sit with the Celadon Pharmaceuticals board and management team rather than a Summerway investment committee. The key operators are the executives running the cultivation facility, quality systems, and commercial partnerships. Because the firm is a single-asset operating company listed on AIM, material decisions are subject to board approval and, in certain cases, shareholder consent under AIM rules.